Apellis Pharmaceuticals

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals

Friday, November 21, 2014

Apellis Pharmaceuticals, a Crestwood, Ky.-based, clinical stage immunotherapy company, will acquire Potentia Pharmaceuticals, an early stage biotechnology company also located in Crestwood. Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD).

[Read More]